<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603016</url>
  </required_header>
  <id_info>
    <org_study_id>PLAGHS201503601</org_study_id>
    <nct_id>NCT02603016</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma</brief_title>
  <official_title>Phase 1 Study of Clinical Nutrition That Research Safty and Efficacy in Lung Neoplasms And Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast
      carcinoma.We estimate there will be 480 patients accepted.120 patients will receive GLSE
      compound,120 patients will recrive Maitake mushroom extract compound,120 patients will
      recrive Rinseng compound,and 120 patients will be as blank countrol group.Efficacy Study of
      Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GLSE compound、Maitake mushroom extract compound and Rinseng compound have different mechanism
      on enhancing immunity.This clinicaltrial compare them the immune effect in the progress of
      treating lung neoplasms and breast carcinoma.Within the 42 days,we will abide by the plan to
      evaluate the immunity enhancement by monitoring mmune effector molecules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T-lymphocyte cell subsets</measure>
    <time_frame>three mouths</time_frame>
    <description>T-lymphocyte cell subsets contains CD3+、CD4+、CD8+、CD28-、CD28+、CD4+CD25+、HLADR+、HLADR-,measured these cells concentration level</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>GLSE compound group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLSE compound 2g each time by mouth,twice a day for 42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maitake mushroom extract compound group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ginseng compound group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ginseng compound 2 tables each time by mouth,twice a day for 42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Take nothing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLSE compound</intervention_name>
    <arm_group_label>GLSE compound group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maitake mushroom extract compound</intervention_name>
    <arm_group_label>Maitake mushroom extract compound group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginseng compound</intervention_name>
    <arm_group_label>Ginseng compound group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lung cancer and breast cancer patients confirmed by surgery pathology;

          -  ECOG physical stamina score of 0~3 points;

          -  Expected lifetime &gt; 3 months;

          -  Need to receive radiation and chemotherapy;

          -  Heart, liver and kidney function and blood picture is normal,WBC≥4×109/L, neutrophil
             count≥ 2 x 109 / L,platelet count≥100×109/L, hemoglobin≥100 g/L;

          -  To follow-up, good adherence

        Exclusion Criteria:

          -  Allergic to text drug;

          -  Pregnancy or lactation women;

          -  Suffering from mental illness of not easy to control,

          -  Have serious mental or cognitive dysfunction;

          -  Can not comply with the experimental scheme or can't cooperate with the follow-up;

          -  The patients who are unfavorable to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shunchang Jiao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>1000853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>March 11, 2017</last_update_submitted>
  <last_update_submitted_qc>March 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Zhiyong Wu</investigator_full_name>
    <investigator_title>Associate Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Clinical Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

